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Background and purpose: Apathy is an important neuropsychiatric feature of
Parkinson’s disease (PD), which often emerges before the onset of motor
symptoms. Patients with rapid eye movement sleep behaviour disorder (RBD)
have a high probability of developing PD in future. Neuropsychiatric prob-
lems are common in RBD, but apathy has not previously been detailed in this
key prodromal population.
Methods: Eighty-eight patients with polysomnographically proven RBD, 65
patients with PD and 33 controls were assessed for apathy using the Lille
Apathy Rating Scale. Cognition and depression were also quantiﬁed. The sen-
sitivity of the Uniﬁed Parkinson’s Disease Rating Scale screening questions for
apathy and depression was calculated.
Results: A total of 46% of patients with RBD were apathetic, compared with
31% of patients with PD in our sample. Most patients with RBD with depres-
sion were apathetic but more than half of apathetic patients were not
depressed. The sensitivity of the single Uniﬁed Parkinson’s Disease Rating
Scale screening question was only 33% for mild apathy and 50% for severe
apathy.
Conclusions: Apathy is common in RBD and is underestimated by a single
self-report question. Recognition of apathy as a distinct neuropsychiatric fea-
ture in RBD could aid targeted treatment interventions and might contribute
to the understanding of prodromal PD.
Introduction
Apathy is a common and debilitating feature of
Parkinson’s disease (PD) and dementia with Lewy
bodies (DLB), which impacts on the quality of life of
both patients and carers [1–3]. Characterized by
pathological lack of motivation, it manifests as a
reduction in goal-directed thoughts and behaviours,
with or without emotional blunting [4]. Although it
frequently coexists with other neuropsychiatric
conditions, such as depression and cognitive impair-
ment, apathy is increasingly recognized as a distinct
syndrome with diﬀerent aspects that are not always
present [5,6]. It is not equivalent to anhedonia, as
patients with apathy are still able to enjoy activities if
they are prompted to act.
As with many non-motor features of PD and DLB,
apathy is often reported retrospectively to occur
before the onset of motor symptoms [7]. Despite this,
the syndrome has never been formally assessed in the
prodromal period. As well as furthering understanding
of prodromal PD/DLB, recognizing apathy if it occurs
early might lead to interventions with speciﬁc psycho-
logical and pharmacological therapies to improve
quality of life in this phase of disease.
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Patients with rapid eye movement sleep behaviour
disorder (RBD) have a long-term risk exceeding 80%
of developing an alphasynuclein-related neurodegener-
ative disorder, with the majority converting to either
PD or DLB [8]. Patients with RBD therefore present
a valuable opportunity to study the prodromal phase
of these disorders. Although apathy is recognized in
RBD, most studies rely on single-question self-report
measures [9,10], which may fail to capture the full
spectrum of the condition. It is now recognized that
there might be many components of apathy, including
deﬁcits in self-awareness and emotional responses as
well as action initiation and intellectual curiosity [11].
One recent study of RBD demonstrated that
depression, anxiety and cognitive impairment are
particularly common, suggesting that RBD might
represent the prodromal phase of a subtype of alpha-
synucleinopathy with a more severe neuropsychiatric
phenotype [9]. Such parkinsonian non-motor features
may have a role in risk-stratiﬁcation models to predict
conversion to PD/DLB [12]; accurately establishing
the presence and severity of apathy in RBD is there-
fore an important objective.
Apathy might be of particular relevance in prodro-
mal PD/DLB because of the role of dopamine in neu-
ral pathways underlying reward and eﬀort sensitivity
that appear to be key to motivation [13]. Dopaminer-
gic neurodegeneration proceeds for many years prior
to the onset of motor parkinsonism, with more than
50% of substantia nigra neurons having been lost by
the time that motor symptoms emerge [14]. The
mesolimbic pathway is also vulnerable to degeneration
in PD [15], and may have a more speciﬁc role in the
development of neuropsychiatric manifestations [16].
Although neurodegeneration in the mesolimbic system
has not been clearly established in prodromal disease,
it is plausible that deﬁcits caused by early involvement
of this pathway in the disease process may be detect-
able in patients with RBD.
The aim of this study was to investigate the fre-
quency and severity of apathy in a large cohort of
patients with RBD and to compare the results with
patients with PD and healthy controls. We used the
Lille Apathy Rating Scale (LARS) to assess apathy as
it provides the most detailed and structured evaluation
of any rating system, including subdomains of apathy
as well as an overall measure of apathy severity [11].
Unlike some other apathy ratings, it does not rely on
subjective reports of caregivers and therefore has high
inter-rater consistency and excellent accuracy com-
pared with clinical judgement [17]. It can eﬀectively
distinguish apathy from depression and has been vali-
dated in established PD with and without dementia
[11]. In addition, we sought to explore the overlap
between apathy, cognition and depression, and also to
assess the value of a commonly used apathy screening
question from the Uniﬁed Parkinson’s Disease Rating
Scale (UPDRS) I.
Methods
Participants
Patients with RBD were recruited from an established
UK research cohort described elsewhere [18]. They
were recruited to the study from sleep centres at the
John Radcliﬀe Hospital, Oxford and Papworth Hospi-
tal, Cambridge, UK. Patients with PD were recruited
separately from neurology clinics in the Oxfordshire
area. Control participants were recruited from a vol-
unteer database and screened to exclude those with
neurological conditions. All RBD diagnoses were
made by polysomnography according to International
Classiﬁcation of Sleep Disorders criteria [19]. Patients
with RBD were examined by a neurologist to exclude
the presence of PD and other neurological disorders.
Patients with dementia, identiﬁed using a combination
of cognitive testing {Montreal Cognitive Assessment
(MOCA) [20]}, informant ratings (using the Infor-
mant Questionnaire on Cognitive Decline in the
Elderly [21]) and clinical judgement, were not
included. We also excluded patients with RBD with
concomitant moderate or severe obstructive sleep
apnoea (apnoea hypopnea index ≥ 15). The study was
approved by the Oxfordshire Research Ethics Com-
mittee and all participants provided informed, written
consent.
Assessments
Apathy was assessed using the LARS [11]. The scale
includes 33 items, divided into nine domains. The glo-
bal score ranges from 36 to +36, with a higher score
representing a greater degree of apathy. We used the
following cut-oﬀ values for categorical classiﬁcation
as indicated in the validation of the scale: no apathy,
≤22; mild apathy, 21 to 17; moderate to severe
apathy, ≥16. Depression was assessed using the Beck
Depression Inventory (BDI) [22], with a score >13
indicative of depression. Cognitive impairment was
assessed using the MOCA [20]. A threshold for cogni-
tive impairment of <24 on the MOCA was used, as
this value optimizes the speciﬁcity and positive predic-
tive value for mild cognitive impairment [23]. The
Epworth Sleepiness Scale[24] was used to assess day-
time sleepiness in subjects with RBD, with the stan-
dard threshold of >10 indicating excessive daytime
sleepiness. Participants with PD and RBD also
© 2017 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
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completed the Movement Disorders Society UPDRS
[25], including the motor assessment (part III) and the
screening questions for apathy (part I, question 1.5)
and depression (part I, question 1.3). Data from
polysomnography were taken from the diagnostic
studies and were therefore not collected at the same
time as clinical assessments.
Statistical analysis
Between-groups comparisons for continuous variables
were made using linear regression and for dichoto-
mous variables using logistic regression, with gender
(as a categorical variable), age, BDI and MOCA
scores (as continuous variables) included as covariates
where indicated to control for any between-group dif-
ferences that may also impact on apathy ratings.
Comparisons of LARS scores within patient groups
where other variables were not adjusted for were
made using the Mann–Whitney U-test or Kruskal–
Wallis test as appropriate, and the chi-square test was
used for categorical outcomes. Pearson correlation
coeﬃcients were used to assess relationships between
two continuous variables. Sensitivity, speciﬁcity and
positive predictive value of the UPDRS part I screen-
ing questions were calculated using standard formulae,
with a UPDRS I response >0 considered as a positive
screening result. Only cases of RBS and PD, but not
controls, had a UPDRS assessment. Subgroups for
the sensitivity analyses were generated using a fre-
quency-matching process.
Results
Assessments were completed in 88 patients with RBD,
65 age-matched patients with PD and 33 healthy con-
trols. Patients with RBD had a mean duration of 8.5
(SD 6.7) years since symptom onset and 3.0 (SD 2.5)
years since polysomnographic diagnosis. Patients with
PD had mean disease duration since diagnosis of 4.4
(SD 4.0) years and mean total UPDRS score of 41.8
(SD 17.5). A total of 10 patients with PD were drug
naive, 47 were receiving treatment with L-DOPA, 26
with a dopaminergic agonist and 30 were taking other
PD medications (monoamine oxidase inhibitors, cate-
chol-O-methyl transferase inhibitors or amantadine).
The results of clinical assessments are shown in
Table 1. Comparisons between groups for all assess-
ment scores were adjusted for age and gender. In
keeping with previous reports, measures of cognition
and depression were signiﬁcantly worse in patients
with RBD compared with controls. Apathy classed as
mild or worse was present in 45.5% [95% conﬁdence
interval (CI), 34.8–56.4%] of subjects with RBD,
compared with 30.8% (95% CI, 19.9–43.4%) of
patients with PD and only 3.2% (95% CI, 0.1–16.7%)
of control participants. Moderate to severe apathy
was present in 15.9% (95% CI, 9.0–25.2%) of patients
with RBD, 18.5% (95% CI, 9.9–30.0%) of patients
with PD and 3.2% (95% CI, 0.1–16.7%) of control
subjects. Mean total LARS scores in patients with
RBD were signiﬁcantly worse than in controls, and
similar to those in patients with PD. Breakdown of
the LARS scores revealed that patients with RBD
were impaired across all subdomains compared with
controls except the one that seeks to measure emo-
tional apathy where their worse score was consistent
with chance variability. Compared with patients with
PD, action initiation and self-awareness LARS scores
were actually worse in cases of RBD.
Using a LARS score ≥21 as indicative of apathy,
the sensitivity of the UPDRS I apathy screening ques-
tion in patients with RBD was only 33% (95% CI,
19–49%), speciﬁcity was 85% (95% CI, 72–94%),
positive predictive value was 65% (95% CI, 41–85%),
negative predictive value was 60% (95% CI,
48–72%), positive likelihood ratio was 2.2 and nega-
tive likelihood ratio was 0.79. The sensitivity for mod-
erate to severe apathy (LARS score ≥16) was
slightly improved at 50% (95% CI, 23–77%) but with
wide CIs due to relatively small numbers. However,
the sensitivity of the UPDRS screening question for
depression in RBD (deﬁned as BDI score > 13) was
80% (95% CI, 63–98%).
The extent of apathy in patients with RBD was not
explained by excessive daytime sleepiness. There was
no signiﬁcant correlation between LARS scores and
Epworth Sleepiness Scale scores in patients with RBD
as a whole (r = 0.10, P = 0.34) or in apathetic patients
with RBD (r = 0.14, P = 0.40). Furthermore, there
was no evidence for apathy occurring as a result of
disturbed sleep itself, as LARS scores did not corre-
late with polysomnographic measures of sleep quality
(total sleep time: r = 0.04, P = 0.76; sleep eﬃciency:
r = 0.16, P = 0.19; percentage slow-wave sleep:
r = 0.13, P = 0.27).
Forty patients with RBD (45%) were taking clon-
azepam at the time of testing as treatment for RBD
symptoms. Sedation commonly occurs as a side-eﬀect
of clonazepam and may conceivably contribute to
symptoms of apathy. Although patients with RBD
taking clonazepam had higher total LARS scores
(mean 19.8) than those not taking clonazepam
(mean 22.0), this was consistent with chance
(P = 0.07). Furthermore, patients with RBD not tak-
ing clonazepam were still signiﬁcantly more apathetic
than healthy controls (P < 0.001), and showed similar
levels of apathy to patients with PD (P = 0.12),
© 2017 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
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meaning that apathy in RBD cannot be fully
explained as a side-eﬀect of clonazepam.
The overlap between apathy, depression and cogni-
tive impairment in patients with RBD and PD is
shown in Fig. 1. Although these features frequently
coexisted, there was clear dissociation between them.
A total of 33% of patients with RBD had one condi-
tion alone and, crucially, two-thirds of those with apa-
thy were not depressed. Patients with PD in this
sample actually had less cognitive impairment, but the
dissociation between apathy and depression was simi-
lar to that seen in RBD.
To explore the relationship between depression and
apathy further, we examined the correlation between
LARS and BDI scores in the three patient groups. In
control participants there was no correlation (r = 0.0,
P = 0.99), whereas moderate correlations were present
in patients with RBD (r = 0.29, P = 0.007) and PD
(r = 0.46, P < 0.001). Amongst apathetic patients with
RBD, however, there was no signiﬁcant correlation
between the severity of depression and apathy
(r = 0.10, P = 0.53). Moreover, patients with RBD
with depression were not signiﬁcantly more apathetic
than non-depressed patients with RBD (mean LARS
score 19.1 vs. 21.6, P = 0.12). When individuals
with depression (BDI score > 13) were excluded in a
sensitivity analysis, patients with RBD remained sig-
niﬁcantly more apathetic than controls (Table S1).
In the PD group, patients with depression were sig-
niﬁcantly more apathetic than those without depres-
sion (mean LARS score 19.9 vs. 25.0, P = 0.01).
When excluding all patients with depression, patients
with RBD were signiﬁcantly more apathetic than
patients with PD (Table S1). These data suggest that,
although there is an association between apathy and
depression, particularly in PD, apathy in patients with
Table 1 Demographic and neuropsychiatric characteristics
Control
(n = 33)
RBD
(n = 88)
PD
(n = 65)
P value
RBD vs. control
P value
RBD vs. PD
Age (years) 68.4 (8.94) 66.9 (7.62) 66.4 (5.65) 0.31 0.70
Male (%) 45.5 94.3 72.3 <0.001 0.001
UPDRS score n/a 5.25 (4.02) 41.8 (17.5) n/a <0.001
MOCA score 28.3 (1.44) 24.9 (3.08) 27.6 (2.30) <0.001 <0.001
BDI score 4.91 (4.91) 9.40 (7.68) 10.2 (7.01) 0.01 0.48
Total LARS score 29.1 (4.33) 21.0 (6.00) 23.3 (6.85) <0.001 0.10
LARS intellectual curiosity score 3.30 (0.63) 2.37 (0.96) 2.29 (1.07) <0.001 0.41
LARS emotion score 2.62 (1.03) 1.98 (1.13) 2.32 (1.25) 0.10 0.19
LARS action initiation score 3.76 (0.47) 2.77 (1.00) 3.25 (0.89) <0.001 0.005
LARS self-awareness score 3.12 (1.32) 2.03 (1.52) 2.97 (1.32) 0.002 <0.001
Mild apathy (%; LARS score ≥21) 3.0 45.5 30.8 0.008 0.23
Moderate to severe apathy (%; LARS score ≥16) 3.0 15.9 18.5 0.22 0.40
BDI, Beck Depression Inventory; LARS, Lille Apathy Rating Scale; MOCA, Montreal Cognitive Assessment; n/a, not applicable; PD, Parkin-
son’s disease; RBD, rapid eye movement sleep behaviour disorder; UPDRS, Uniﬁed Parkinson’s Disease Rating Scale. Values are mean (SD)
for continuous variables (age, MOCA, BDI, LARS total and subdomain scores) and percentages for dichotomous variables (gender, mild and
severe apathy categories); P values in bold indicate statistically signiﬁcant group diﬀerences at the <0.05 level.
Figure 1 Overlap between apathy,
depression and mild cognitive impair-
ment (MCI) in patients with (a) rapid
eye movement sleep behaviour disorder
(n = 88) and (b) Parkinson’s disease
(n = 65). Apathy is deﬁned as Lille Apa-
thy Rating Scale score ≥21, cognitive
impairment as Montreal Cognitive
Assessment score <24 and depression as
Beck Depression Inventory score >13.
© 2017 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
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RBD cannot be explained simply by the presence of
depression.
There were weak correlations between LARS and
MOCA scores in all of the groups (control: r = 0.20,
P = 0.27; RBD: r = 0.17, P = 0.11; PD: r = 0.17,
P = 0.17), which were consistent with chance. There
was a trend towards more severe apathy in patients
with RBD with cognitive impairment (MOCA
score < 24) than in those without, but this was consis-
tent with random variability (mean LARS score
19.5 vs. 21.8, P = 0.08).
Despite this evidence of dissociation between apa-
thy, depression and cognitive impairment, there
remains some degree of overlap in their clinical fea-
tures. In order to control for this, we repeated the
comparisons between RBD versus PD and RBD ver-
sus controls using a linear regression model that
included BDI and MOCA scores as covariates in
addition to age and gender. The results of this are
shown in Table 2. The same-group diﬀerences in
LARS total scores and subdomains were observed
using this analysis. To further control for group diﬀer-
ences, we undertook additional sensitivity analyses
using two subgroups of patients, the ﬁrst with subjects
matched for age and MOCA scores, and the second
with subjects matched for gender. These are shown in
the Supporting Information (Tables S2 and S3). The
same-group diﬀerences in apathy scores remained,
with patients with RBD always signiﬁcantly more
apathetic than controls and of similar apathy severity
to patients with PD.
One potential confounding variable in the PD
group is the use of dopaminergic medication. Dopa-
mine receptor agonists (DAs), in particular, have been
shown to reduce apathy and may therefore contribute
to lower apathy ratings in the participants with PD
[26]. Table 3 shows the same variables as Table 1,
with patients with PD divided into three groups
according to treatment: drug naive, those taking DAs
(with or without L-DOPA) and those taking L-DOPA
without agonists. Patients with PD taking DAs were
less apathetic than drug-naive patients and those tak-
ing L-DOPA, although there was no signiﬁcant eﬀect
of treatment type (Kruskal–Wallis test across patients
with PD by treatment type, P = 0.21). However,
patients with PD taking DAs were signiﬁcantly less
apathetic than patients with RBD (mean LARS score
24.4 vs. 21.0, P = 0.003).
To remove any eﬀect of DAs on overall group apa-
thy ratings, we performed a comparison between
patients with RBD and PD excluding those taking DAs
(Table 3). There remained no signiﬁcant diﬀerence in
overall LARS scores. With respect to the whole-group
comparison, the diﬀerence in action initiation subscores
was no longer signiﬁcant, but patients with RBD
remained signiﬁcantly worse in the self-awareness sub-
score. We conclude that some of the apparent diﬀer-
ences between RBD and PD may reﬂect dopaminergic
therapy (making the PD group appear less apathetic)
but, even without the eﬀect of DAs, patients with RBD
are at least as apathetic as patients with PD.
Within the PD group, there was evidence of an
association between apathy and disease severity;
UPDRS motor scores (part III) were positively corre-
lated with LARS scores (r = 0.29, P = 0.02) and this
eﬀect remained after adjusting for age (P = 0.02).
There was no such relationship in patients with RBD
(r = 0.03, P = 0.75) but, as these patients do not have
signiﬁcant motor parkinsonism, UPDRS III score is
not a sensitive measure of prodromal disease stage.
To determine whether apathy in RBD is associated
with increased risk of developing PD will require
long-term follow-up.
Discussion
In the ﬁrst study to quantify the extent and severity
of apathy in RBD, we have shown that the condition
Table 2 Apathy scores with group comparisons adjusted for age, gender, Beck Depression Inventory (BDI) and Montreal Cognitive
Assessment (MOCA) scores
Control
(n = 33)
RBD
(n = 88)
PD
(n = 65)
P value
RBD vs. control
P value
RBD vs. PD
Total LARS score 29.1 (4.33) 21.0 (6.00) 23.3 (6.85) 0.002 0.35
LARS intellectual curiosity score 3.30 (0.63) 2.37 (0.96) 2.29 (1.07) 0.01 0.45
LARS emotion score 2.62 (1.03) 1.98 (1.13) 2.32 (1.25) 0.44 0.57
LARS action initiation score 3.76 (0.47) 2.77 (1.00) 3.25 (0.89) 0.02 0.05
LARS self-awareness score 3.12 (1.32) 2.03 (1.52) 2.97 (1.32) 0.02 0.02
Mild apathy (%; LARS score ≥21) 3.0 45.5 30.8 0.05 0.41
Moderate to severe apathy (%; LARS score ≥16) 3.0 15.9 18.5 0.76 0.17
LARS, Lille Apathy Rating Scale; PD, Parkinson’s disease; RBD, rapid eye movement sleep behaviour disorder. Values are mean (SD) for
continuous variables (age, MOCA, BDI, LARS total and subdomain scores) and percentages for dichotomous variables (gender, mild and
severe apathy categories); P values in bold indicate statistically signiﬁcant group diﬀerences at the <0.05 level.
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is both common and under-recognized. Approximately
half of all patients with RBD in this cohort were
aﬀected by apathy, a prevalence similar to that seen
in established PD in our sample. The presence of apa-
thy in RBD was not explained by excessive daytime
sleepiness, poor sleep quality or sedative medication.
Amongst subdomains of apathy, all were impaired in
RBD except emotional responses, suggesting that
problems with motivation for action, intellectual
curiosity and self-awareness, rather than aﬀect, pre-
dominate in patients with RBD.
Our data suggest that the single screening question
for apathy in the UPDRS assessment has modest sen-
sitivity, capturing only one-third of all apathetic
patients with RBD and just half of those with moder-
ate to severe apathy, and a relatively weak positive
likelihood ratio. This is in contrast to the UPDRS
screening question for depression, which was 80%
sensitive in this study. There are a number of possible
explanations for this. First, the UPDRS question asks
only about ‘indiﬀerence to doing activities or being
with people’ and therefore may not capture other sub-
domains of apathy. Secondly, apathy might be associ-
ated with reduced insight compared with depression
as a result of impaired self-awareness, which would
limit the sensitivity of self-report measures. Finally, it
may be accounted for in part by the high rate of cog-
nitive impairment in RBD, as studies of apathy in
other populations have shown discordance between
self-report and clinician-rated measures of apathy in
cognitively impaired individuals [27].
Although there is signiﬁcant overlap between apa-
thy, depression and cognitive impairment, these are
clearly dissociable; only 33% of apathetic patients
with RBD were depressed and less than half had cog-
nitive impairment. Furthermore, diﬀerences in the
degree of apathy between patient groups could not be
explained by diﬀerences in cognition and depression.
This evidence of apathy as a distinct neuropsychiatric
syndrome highlights the importance of actively look-
ing for apathy even when other neuropsychiatric fea-
tures are absent. It also raises the possibility that,
where apathy coexists with depression and/or cogni-
tive impairment, these are distinct manifestations of a
common underlying neurodegenerative process rather
than a single neuropsychiatric condition.
The association between apathy and severity of
motor disease in patients with PD suggests that apa-
thy may be related to disease progression. The fact
that patients with RBD were as apathetic as those
with PD, in our sample, is not inconsistent with this,
despite them being at an earlier neurodegenerative
stage. Accumulating evidence suggests that patients
with PD who develop RBD ﬁrst might represent a dis-
tinct subtype of disease with a more severe non-motor
phenotype, and that many of these non-motor fea-
tures emerge prior to the onset of motor parkinsonism
[28,29]. In keeping with this hypothesis, we recently
Table 3 Distribution of apathy scores in patients with Parkinson’s disease (PD) according to treatment type
Control
(n = 33)
RBD
(n = 88)
PD
drug naive
(n = 10)
PD
agonist L-DOPA
(n = 26)
PD
L-DOPA
without DA
(n = 26)
P value
across
three PD
groups
P value
patients
with RBD vs.
PD not taking DA
Age (years) 68.4 (8.94) 66.9 (7.62) 64.8 (7.19) 65.8 (5.70) 67.3 (5.10) 0.37 0.98
Male (%) 45.5 94.3 50 69 81 0.18 0.003
MOCA score 28.3 (1.44) 24.9 (3.08) 25.9 (3.14) 28.3 (1.93) 27.7 (2.09) 0.04 <0.001
BDI score 4.91 (4.91) 9.40 (7.68) 11.1 (7.79) 9.0 (7.07) 11.0 (6.59) 0.44 0.29
Total LARS score 29.1 (4.33) 21.0 (6.00) 23.2 (7.61) 24.4 (6.84) 21.8 (6.50) 0.21 0.39
LARS intellectual
curiosity score
3.30 (0.63) 2.37 (0.96) 2.53 (1.24) 2.37 (0.94) 2.12 (1.12) 0.42 0.63
LARS emotion score 2.62 (1.03) 1.98 (1.13) 1.85 (1.55) 2.56 (1.40) 2.17 (0.94) 0.10 0.79
LARS action
initiation score
3.76 (0.47) 2.77 (1.00) 3.25 (0.95) 3.48 (0.66) 3.00 (1.07) 0.28 0.23
LARS self-awareness
score
3.12 (1.32) 2.03 (1.52) 2.90 (1.29) 2.88 (1.48) 2.96 (1.25) 0.97 0.006
Mild apathy
(%; LARS score ≥21)
3.0 45.5 30 19 42 0.20 0.74
Severe apathy
(%; LARS score ≥16)
3.0 15.9 20 12 27 0.37 0.16
BDI, Beck Depression Inventory; DA, dopamine receptor agonist; LARS, Lille Apathy Rating Scale; MOCA, Montreal Cognitive Assessment;
RBD, rapid eye movement sleep behaviour disorder; UPDRS, Uniﬁed Parkinson’s Disease Rating Scale. Values are mean (SD) for continuous
variables (age, MOCA, BDI, LARS total and subdomain scores) and percentages for dichotomous variables (gender, mild and severe apathy
categories); P values in bold indicate statistically signiﬁcant group diﬀerences at the <0.05 level.
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demonstrated that a wide range of non-motor features
are as severe in RBD as they are in newly diagnosed
PD, and that depression and anxiety are worse in
RBD [9]. In a separate study of patients with estab-
lished PD, we found that apathy was signiﬁcantly
more common in patients with PD with concomitant
RBD than in those without [30]. The co-occurrence of
RBD and other non-motor features might be a conse-
quence of more widespread Lewy body pathology in
these patients, aﬀecting brain regions involved in the
regulation of sleep, cognition and mood in addition to
motor control [31].
A potential underlying mechanism for apathy in
RBD is the degeneration of dopaminergic neurons
involved in motivation and reward/eﬀort-based deci-
sion-making pathways. In established PD there is con-
siderable evidence for the importance of dopamine
dysfunction in apathy. Functional imaging studies
have demonstrated greater dopaminergic deﬁcits in
apathetic patients with PD than in patients with PD
without apathy [32,33], and dopaminergic agonists
have been proven to partially alleviate symptoms of
apathy in PD [26]. The ventral striatum and dorsal
anterior cingulate cortex appear to be key regions
involved in generating motivated behaviour [34], and
dysfunction in striatofrontal functional connectivity
has been shown to associate with apathy in patients
with PD [35]. Although the dopaminergic motor sys-
tem displays considerable capacity for compensation
in the prodromal phase of PD, it is possible that deﬁ-
cits in these motivational pathways emerge at an ear-
lier stage of dopamine depletion. Future work with
functional neuroimaging in patients with RBD will be
important to shed light on the relationship between
apathy and dysfunction in these brain regions.
Recognition of apathy as a distinct neuropsychiatric
condition is important as it may guide the choice of
both psychological and pharmacological interventions.
Although few interventional trials have been con-
ducted on apathy, there is evidence that, in depressed
patients with motivational problems, behavioural acti-
vation techniques may be superior to standard cogni-
tive behavioural therapy, and medications with
dopaminergic eﬀects may have greater eﬃcacy than
selective serotonin reuptake inhibitors [36]. This might
be particularly relevant in patients with RBD when a
dopaminergic deﬁcit is revealed, e.g. using nuclear
imaging. Further studies are needed to identify the
most eﬀective treatments for apathy.
An important ﬁnding to be established from future
follow-up of our cohort will be the extent to which
apathy predicts conversion to neurodegenerative dis-
orders. Depression (with or without anxiety) and
excessive daytime somnolence have been shown to
increase risk of conversion in patients with RBD, and
these features are included in the Movement Disorders
Society Research Criteria for prodromal PD [12].
Longitudinal study of conversion from RBD to PD in
our participants will be important in establishing
whether apathy may form an equally important part
of such risk-stratiﬁcation models.
A limitation of our study should be noted. Accu-
rately matching across all three groups for age, gen-
der, depression and cognition was not feasible given
the way that these variables are diﬀerentially dis-
tributed amongst the populations studied. RBD is
diagnosed predominantly in males [28], and it is
expected that measures of cognition and depression
will be worse in RBD than controls [37,38]. The fact
that our RBD group had lower MOCA scores than
the PD group is perhaps more surprising, but it
should be noted that patients with RBD are as likely
to develop DLB as PD, and the extent of cognitive
impairment in patients with RBD may reﬂect this [39].
We have controlled as much as possible for the group
diﬀerences by including all variables in our regression
model where appropriate, and by performing sensitiv-
ity analyses, but it is still possible that some of the
variation in apathy is accounted for by diﬀerences in
these other characteristics.
In summary, we have shown that apathy is a com-
mon and under-recognized feature of RBD and
should be actively sought as part of the clinical phe-
notype of this disorder. Longitudinal follow-up will
establish the extent to which apathy may herald con-
version to PD or a related neurodegenerative disorder.
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